Pfizer Testing Lyme Disease Vaccine Candidate in Phase 3 Trial
VLA15 is a 6-valent protein subunit vaccine that targets the outer surface protein A of Borrelia burgdorferi.
Infectious Disease
Persistence of Somatic Symptoms After COVID-19 Quantified
Persistent somatic symptoms could be attributed to COVID-19 in an estimated 12.7 percent of patients at 90 to 150 days after COVID-19
In COVID ‘Rebound,’ Biden Tests Positive for Second Day in a Row
Despite the test results, the president ‘has experienced no reemergence of symptoms and continues to feel quite well’
FDA Extends Shelf-Life of Certain Lots of COVID-19 Antiviral Paxlovid
The extended shelf-life of Paxlovid is authorized for 4 lots that were manufactured with a 9-month expiry prior to the issuance of Emergency Use Authorization.
Vaccines for Monkeypox Prevention: Jynneos and ACAM2000
An individual is considered fully vaccinated about 2 weeks after the second dose of Jynneos and 4 weeks after receiving ACAM2000.
Manifestations of Monkeypox Described in Case Series
95 percent of 528 cases presented with rash; 73 and 41 percent had anogenital and mucosal lesions, respectively
First US Polio Case in Nearly a Decade Reported in New York
Investigators now working to determine specifically how the infection happened and whether others were exposed
Two Case Series Describe Acute Pediatric Hepatitis of Unknown Cause
Unclear whether human adenovirus is the causative agent for acute hepatitis in these children
Hypertension Ups Odds of Omicron-Variant COVID-19 Hospitalization
Observational study findings highlight a “persistent and marked” association between hypertension and risk for severe COVID-19, even among fully vaccinated patients, according to investigators.
CDC: Protein-Based Novavax COVID-19 Vaccine Recommended for Adults
The Novavax COVID-19 Vaccine, Adjuvanted is administered intramuscularly as a 2-dose primary series (0.5mL each), separated by 3 weeks.
